Key Points
-
The transaction involved the disposal of 95,798 shares with an estimated value of about $2.7 million based on the transaction date market close.
-
The transaction was non-discretionary, executed to cover tax obligations related to the vesting and settlement of restricted stock units (RSUs).
-
Elshenawy continues to hold 194,000 shares directly and maintains roughly 2 million additional derivative securities.
- 10 stocks we like better than Hims & Hers Health ›
CTO Mohamed Elshenawy reported a non-discretionary sale of 95,798 shares of Hims & Hers Health, Inc. (NYSE:HIMS) at $28.15 per share on August 14, according to a recent SEC Form 4 filing.
Transaction summary
MetricValueTransaction value$2.7 millionShares disposed (directly held)95,798Post-transaction shares (directly held)193,510Post-transaction value$5.45 million
Transaction value based on SEC Form 4 weighted average sale price ($28.15); post-transaction value based on the August 14 market close ($28.15).
Key questions
- What was the primary driver of this transaction?The disposal was a non-discretionary event focused on satisfying tax withholding requirements triggered by the vesting of equity awards and does not reflect the insider’s discretionary view on the company’s valuation.
- How is the insider’s remaining equity structured?The reporting owner maintains direct ownership of 193,510 shares, while also holding roughly 2 million derivative securities that are subject to multi-year service-based vesting schedules.
- What is the schedule for future vesting installments?The underlying restricted stock units vest in quarterly installments over three-to-four-year cycles, suggesting a baseline of recurring non-discretionary tax withholding activity as subsequent tranches settle.
Company Overview
MetricValueShare Price (as of market close 2026-08-17)$28.61Market Capitalization$6.4 billionRevenue (TTM)$2.6 billionNet Income (TTM)-$142.0 million
Company Snapshot
- Hims & Hers operates a comprehensive digital health platform that delivers prescription medications, over-the-counter drugs, medical devices, cosmetics, and dietary supplements directly to consumers through its websites and mobile application.
- The company generates revenue through a direct-to-consumer model by connecting patients with licensed medical professionals for virtual consultations and facilitating the sale of health and wellness products with recurring subscription and transaction-based revenue streams.
- The company primarily serves consumers seeking convenient, accessible healthcare solutions and wellness products, targeting individuals who prefer digital-first medical consultations and home delivery of pharmaceutical and consumer health products.
Hims & Hers Health operates as a leading digital health platform with a $6.4 billion market capitalization and $2.6 billion in TTM revenue, positioning itself at the intersection of telehealth and direct-to-consumer pharmaceutical distribution. The company’s integrated platform model creates competitive advantages through operational efficiency, customer convenience, and data-driven personalization. Despite current net losses of $142.0 million TTM, the company’s substantial revenue base and market scale reflect strong consumer adoption of its digital-first healthcare delivery model.
What this transaction means for investors
ElShenawy’s disposal lines up almost exactly with a filing from CEO Andrew Dudum’s on the same date, with the same $28.15 weighted average price and the same non-discretionary tax withholding on vested RSUs, further signaling that this really wasn’t a discretionary call at all. Quarterly vesting cycles the whole leadership team through withholding sales in the same window, so a cluster here is basically just payroll admin.
What’s actually worth watching is ElShenawy’s own project. As CTO, he’s the one rebuilding Hims & Hers around AI, and on the August 10 call his own description was blunt. “We are making AI load-bearing, not decorative.” That investment is already visible in the numbers, technology and development spending rose to $54.9 million in the quarter, and CFO Yemi Okupe has said management expects the AI spending to pay back within 12 to 18 months. It’s funding a real trade-off, too. Gross margin fell to 64% from 76% a year earlier as the mix shifted toward branded weight-loss and international revenue, and Okupe has said compression will persist through the back half of the year. Ultimately, ElShenawy’s stock movement tells you nothing here; instead, his technology roadmap and whether it earns back that margin are what matter.
Should you buy stock in Hims & Hers Health right now?
Before you buy stock in Hims & Hers Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $409,970!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,381,040!*
Now, it’s worth noting Stock Advisor’s total average return is 969% — a market-crushing outperformance compared to 215% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool has a disclosure policy.